# Reversal to Normoglycemia by Treating Prediabetes

> **NCT07392151** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Michael Mæng** · enrollment: 158 (estimated)

## Conditions studied

- Prediabetes
- Chronic Coronary Syndrome

## Interventions

- **DRUG:** Intensified medical follow-up and glucose-lowering drugs
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT07392151
- **Lead sponsor:** Michael Mæng
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392151, "Reversal to Normoglycemia by Treating Prediabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07392151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*